1:45 PM (PT)
-
Our industry has faced a variety of geopolitical and economic issues that inject uncertainty into deal-making. We must now navigate an unprecedented wave of legislation, executive orders, and policies ...Breakout Session
-
Business Development and Investment
-
)
)
)
)
)
3:00 PM (PT)
-
In biotech, success often hinges on spotting opportunities before anyone else does. Some of the industry’s most impactful companies have been built with smart business development regardless of their ...Breakout Session
- Business Development and Investment
-
)
.jpg/fit-in/120x9999/filters:no_upscale())
)
)
4:15 PM (PT)
-
After two years of a quiet IPO window, the biotech markets are showing renewed signs of life. A growing number of companies are testing public waters again — but with tighter investor scrutiny, leaner ...Breakout Session
- Business Development and Investment
-
)
.jpg/fit-in/120x9999/filters:no_upscale())
)
)
)
.jpeg)
11:00 AM (PT)
-
As the next wave of patent cliffs loom, the pressure is on pharma to secure late-stage assets that deliver near-term value. Meanwhile, biotech leaders are navigating tighter capital markets and evolvi ...Breakout Session
- Business Development and Investment
-
-
As major patent expirations loom, pricing pressures intensify and R&D productivity comes under strain, large pharmaceutical companies are accelerating dealmaking to fill therapeutic and clinical-stage ...Breakout Session
- Business Development and Investment
-
-
Super SessionJoin Johnson & Johnson’s John Reed, MD, PhD, Executive Vice President, Innovative Medicine, R&D, and Nauman Shah, Global Head of Business Development, for a discussion on how the company brings togeth ...Super Session
- Business Development and Investment
-
.jpg/fit-in/120x9999/filters:no_upscale())
)
)
)
)
)
)
)
)
1:45 PM (PT)
-
This data-driven session from BIO and its market intelligence partner, Norstella, will dive into the state of play for emerging biotech companies. From venture capital and public financing, deal-makin ...Breakout Session
- Business Development and Investment
-
)
.jpg/fit-in/120x9999/filters:no_upscale())
4:15 PM (PT)
-
AI-enabled discovery and multi-modal, human-centric datasets are driving the next wave of biopharma partnerships. Collaborations are expanding rapidly, characterized by larger upfronts, equity-linked ...Breakout Session
- Business Development and Investment
-
-
Many Western biopharma leaders look back and wish they had engaged earlier with the China story. A similar inflection point is now unfolding in Korea, and the time to engage early is now. South Korea ...Breakout Session
-
Emerging Opportunities in Global Markets
-
)
)
.jpg/fit-in/120x9999/filters:no_upscale())
)
)
.jpg/fit-in/120x9999/filters:no_upscale())
.jpeg)
.jpeg)
.jpg/fit-in/120x9999/filters:no_upscale())
)
)
.jpg/fit-in/120x9999/filters:no_upscale())
11:00 AM (PT)
-
As the global biotech ecosystem becomes increasingly interconnected, in-licensing has evolved into a core growth engine, with US–Asia deal-making and NewCo formation continuing to accelerate as compan ...Breakout Session
- Business Development and Investment
-
)
)
)
12:15 PM (PT)
-
Super SessionSaudi Arabia is rapidly emerging as one of the most compelling pharmaceutical and biotech markets globally. This session brings together global and local industry leaders to explore the deal structure ...Super Session
- Emerging Opportunities in Global Markets
-
)
)
)
1:45 PM (PT)
-
Oncology continues to be the leading therapeutic area across the biopharma industry by almost all measures, including global drug sales, number of pipeline programs, venture capital dollar deployment, ...Breakout Session
-
Oncology
-
.jpg/fit-in/64x9999/filters:no_upscale())
)
)
)
)
3:00 PM (PT)
-
For 87 years, our industry had to operate under an uncomfortable truth: over 90% of cancer drugs that "cure" mice routinely fail patients in clinical trials. In 2022, the FDA Modernization Act 2.0 too ...Breakout Session
- Oncology
-
-
AI technologies are no longer a peripheral concept in drug discovery – these platforms are a driving force for innovative companies reshaping the way we identify targets, and design, optimize, and val ...Breakout Session
-
AI and Digital Health
-
)
)
)
)
.jpg/fit-in/64x9999/filters:no_upscale())
)
)
.jpg/fit-in/120x9999/filters:no_upscale())
)
4:15 PM (PT)
-
Super SessionThis session will shed light on the recent acquisition of Akero Therapeutics by Novo Nordisk. The two panelists played a key role in forging this deal and will share their perspective on the journey t ...Super Session
- Business Development and Investment
-
)
9:00 AM (PT)
-
Even though orphan drugs currently account for almost 50% of all new medicine approved in USA and EU, many conditions still lack therapeutic options, and it has been estimated that 90-95% of the more ...Breakout Session
-
Orphan and Rare Disease
-
)
)
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}